As it displays progressive hair-cell loss and degeneration of spiral ganglion neurons (SGNs) characterized by earlyonset progressive hearing loss (ePHL), DBA/2J is an inbred mouse strain widely used in hearing research. Mouse nerve growth factor (mNGF), as a common exogenous nerve growth factor (NGF), has been studied extensively for its ability to promote neuronal survival and growth. To determine whether mNGF can ameliorate progressive hearing loss (PHL) in DBA/2J mice, saline or mNGF was given to DBA/2J mice of either sex by daily intramuscular injection from the 1st to the 9th week after birth. At 5, 7, and 9 weeks of age, in comparison with vehicle groups, mNGF groups experienced decreased auditory-evoked brainstem response (ABR) thresholds and increased distortion product otoacoustic emission (DPOAE) amplitudes, the prevention of hair cell loss, and the inhibition of apoptosis of SGNs. Downregulation of Bak/Bax and Caspase genes and proteins in cochleae of mice receiving the mNGF treatment was detected by real-time PCR, Western blot, and immunohistochemistry. This suggests that the Bak-dependent mitochondrial apoptosis pathway may be involved in the otoprotective mechanism of mNGF in progressive hearing loss of DBA/ 2J mice. Our results demonstrate that mNGF can act as an otoprotectant in the DBA/2J mice for the early intervention of PHL and, thus, could become of great value in clinical applications. V C 2017 Wiley Periodicals, Inc.
INTRODUCTION
Although more than 5% of the world's population-360 million people-suffer from disabling hearing loss (WHO Fact sheet), there currently is no effective FDA-approved drug to treat it. Mouse models play a crucial role in understanding the pathogenesis associated with hearing disorders (Angeli et al., 2012) , and the DBA/2J mouse strain is one of the most widely used models for hearing research (Johnson et al., 2008) . The DBA/2J mouse strain harbors the Cdh23 753A (ahl) variant and a missense mutation of the fascin-2 gene (ahl8, or Fscn2 R109H ), both of which affect hair cell stereociliary bundle function and stability (Johnson et al., 2008; Shin et al., 2010) . CDH23 is a component of stereocilia tip link, and the FSCN2 protein is an abundant actin cross linker in hair-cell stereocilia. Fscn2
R109H is unique to the SIGNIFICANCE Most progressive hearing loss that results from sensorineural damage is irreversible and currently has no proven cure. Although nerve growth factor (NGF) has been studied extensively for promoting neuronal survival and growth, we do not know its otoprotective effect in progressive hearing loss (PHL) . In this article, we show that mouse nerve growth factor (mNGF) can attenuate hearing loss through the Bakdependent mitochondrial apoptosis. Our findings suggest that mNGF can provide a new mode for ameliorating hearing loss and act as an otoprotectant for AHL. DBA/2J inbred strain and accelerates hearing loss only in the presence of Cdh23 ahl homozygous, which causes a much earlier onset and more rapid progression of hearing loss than C57BL/6J mice (that only have the Cdh23 ahl allele). A QTL on Chr 5 (M5ahl8) modifies its effect on the severity of hearing loss associated with the Fscn2 R109H variant. (Johnson et al., 2015) The hearing loss in the DBA/2J mice strain begins at approximately 3 weeks of age, with deterioration to total deafness by 3 months of age, as we previously reported (Johnson et al., 2008; Zheng et al., 1999) . In DBA/2J mice, hearing loss begins in the high-frequency region and progressively spreads toward the low frequencies, accompanied by progressive degeneration of hair cells and spiral ganglion neurons (SGNs) that begin at the base turn and spread to the apex of the cochlea (Someya et al., 2009) . A recent study showed that the apoptosis of neurons caused by mitochondrial dysfunction contributes to hearing loss (Raimundo et al., 2012) .
Nerve growth factor (NGF) is one of the most well studied neurotrophic factors to date. A study showed that NGF is essential for viability, differentiation, and maintenance in nerve cells (Doerks et al., 2002) . Additionally, it contributes to the repair of the nervous system (Verge et al., 1996) . Moreover, NGF may be implicated in interactions between auditory receptors and efferent innervation of the developing cochlea (Despres et al., 1991) . Tropomyosin receptor kinase (Trk) receptors are a family of tyrosine kinases that regulate synaptic strength and plasticity in the mammalian nervous system (Huang and Reichardt, 2003) . Trk receptors affect neuronal survival and differentiation through several signal cascades. It is suggested that NGF binds to TrkA and p75 NTR (Bothwell, 1995) . Many reports have shown signals related to NGF when binding with the TrkA receptor, becoming phosphorylated and sending a signal downstream, thus causing Akt transformation to phospho-Akt, resulting in increased cell survival (Datta et al., 1997; del Peso et al., 1997; Greene and Kaplan 1995) . The antibody p75 NTR can increase the binding affinity of NGF to TrkA, thus raising the intracellular signal transduction (Hantzopoulos et al., 1994) . However, the JNK/P53/ Bax pro-apoptotic pathways, mediated by p75 NTR , induce the mitochondrial apoptosis and causes cell apoptosis. A study showed that overexpression of NGF and TrkA could inhibit the apoptosis function of p75 NTR and activate the signal that promotes peripheral nerve cell survival (Park et al., 2007) . During the development of the embryo, both NGF and its receptors are widely expressed in the inner ears; levels decrease after birth and remain at low in adulthood. NGF may be involved in the differentiation of acoustic ganglion cells and hair cells (Bernd and Represa, 1989) . Therefore, we hypothesized that supplementation with NGF can inhibit neuron damage and can even protect against hearing loss.
To date, the only effective therapies available to treat hearing loss are hearing aids and the cochlear implant auditory prosthesis for severe hearing loss. The mNGF treatment used as a preventative measure is a new method of ameliorating hearing loss, thus improving the quality of life. However, clinicians cannot easily understand the usage of mNGF because of the unclear mechanism(s). As such, the aim of our study was to evaluate the ameliorative effects produced by mNGF on auditory dysfunction in a progressive hearing loss model and provide evidence of the possible mechanism(s) related to mNGF in auditory neural protection and survival by evaluating genes/proteins to be altered by mNGF with Real-time PCR, Western Blot and Immunohistochemistry.
MATERIALS AND METHODS

Mouse Preparation
DBA/2J mice (RRID: IMSR_JAX:000671) were originally purchased from the Model Animal Research Center of Nanjing University and then relocated to Binzhou Medical University for breeding in specific, pathogen-free animal rooms. The room temperature was maintained at 24 6 1 8C and sufficient food and water were provided. A total of 186 DBA/2J mice aged 1 week were divided into the mNGFtreated group (n 5 78), the vehicle group (n 5 78), and the non-treated group (n 5 30). The animal studies were conducted by the principles outlined in the Guide for the Care and Use of Laboratory Animals of Binzhou Medical University and were approved by the Institutional Animal Use and Care Committee of Binzhou Medical University. The classic exogenous NGF mouse nerve growth factor (mNGF; sharing a 90% homologous amino acid sequence with the NGF of humans) is extracted from the submaxillary gland of male mice. A saline solution of mNGF was administered by intramuscular injection (64.8lg/kg daily) to mice that were 1 to 9 weeks old, as per manufacturer instructions (S20060052 Sinobioway Medicine).
Auditory-evoked brainstem response (ABR) and distortion product oto-acoustic emission (DPOAE). The ABR of the DBA/2J mice was measured at 5, 7, and 9 weeks of age in the mNGF-treated group, the vehicle group, and the non-treated group (5 males, 5 females, n 5 10 for each group), by a person blind to the treatments. A computer-aided evoked potential system (Intelligent Hearing Systems) was used to test mice for ABR thresholds, as previously described Zheng et al., 1999) . The mice were briefly anesthetized with 4% chloral hydrate, and by placing them on a heating pad in a sound-attenuating chamber, their body temperature was maintained at 37-38 8C. Subdermal needle electrodes were inserted at the vertex (active), ventrolaterally to the right ear (reference), and to the left ear (ground). Clicks and 8-, 16-, and 32-kHz tone bursts were channeled through plastic tubes into the animals' ear canals. Alternating clicks (0.1 ms duration) were delivered through earphones (Etymotic ER-2A) at a rate of 19.3 stimuli/s. A half cosine square window was used to create tone burst signals with 3 ms durations (1.5 ms rise-fall with no plateau). Physiological filters were set to pass electrical activity between 100 and 3000 Hz. Monaural responses were recorded for each mouse and averaged in an 11.80 ms time window. One thousand sweeps were collected. The amplified brainstem responses were averaged by a computer and displayed on a computer screen. Auditory thresholds were obtained by decreasing the sound pressure level (SPL) by 10 dB. When no response was detected, the SPL was increased or decreased by 5 dB until a response was determined. The threshold was defined as the lowest intensity at which a visible ABR wave was seen. We recorded the ABR after comparing the ABR patterns with two or three suprathreshold ABRs, displayed successively on the screen. ABR threshold values above 55 (for click stimulus), 40 (for 8 kHz), 35 (for 16 kHz), or 60 (for 32 kHz) dB SPL were considered hearing impaired Zheng et al., 1999) .
To test the function of outer hair cells (OHCs) of different mice at different time points, we used the IHS Smart EP 3.30 and USB ez Software (Intelligent Hearing Systems) for DPOAE measurement, which was conducted for pure tones from 4 to 36 kHz (Polak et al., 2004) . Frequencies were presented with an F2/F1 ratio of 1.22. The stimuli were presented starting with the lowest frequencies tested and were increased to the highest frequencies tested. The DPOAE amplitude, which displayed as DP on the screen, was recorded after repeating two times.
After ABR and DPOAE hearing measurements were performed, all mice were used to conduct histopathological and SGNs counting (n 5 5), hair cell counting (n 5 5), TUNEL staining (n 5 4), real-time PCR (n 5 5), and western blotting (n 5 4) or Immunohistochemistry (n 5 3) analyses (Fig. 1) .
Histological Analyses of Inner Ears
Histological analyses of inner ears were performed following the methods described previously (Zheng et al., 2009) . Briefly, the cochlea was excised, immersed in a fixative containing 4% paraformaldehyde in PBS solution for 1 day, and decalcified in 10% EDTA for 1 week. The time points selected were 5, 7, and 9 weeks of age. Sections (5lm) were mounted on glass slides and counterstained in hematoxylin and eosin (HE). Hair cells, spiral ganglion cells, and stria vascularis were observed under light microscopy (Leica DMI4000 B). SGN counts were carried out following the methods described previously (Semaan et al., 2013) . The average value in four sections approaching the maximum area from a turn of each animal's cochlea was defined as the density for that turn. The SGN size was taken into account when computing the SGN packing density. The correction factor was determined by dividing the section thickness (5 lm) by the sum of the section thickness and the average diameter of the neuronal nucleus: T/T 1 H, where T is section thickness and H is the average nuclear diameter. The average nuclear diameter was determined separately for each group by measuring the diameter of numerous nuclei in midmodiolar sections of Rosenthal's canal selected randomly. To compare mNGF treatment-related changes in stria vascularis width, the thickest portions of the stria vascularis were selected and measured with the aid of Image J software (http://rsb.info. nih.gov/ij/index.html; RRID:SCR_003070).
Cytocochleograms
Organs of Corti were prepared by carefully microdissected them out; then subdivided them into a base turn, a middle turn, and an apex turn; and then mounting them on glass slides in a Shandon Immu-Mount (Thermo). The surface preparations were first stained for F-actin with Alexa Fluor 488 conjugated to phalloidin (1:500 dilution) for 1 hr at room temperature. They were protected from light, mounted after washing twice in 0.01 M phosphate-buffered saline (13 PBS), and finally observed with a confocal fluorescence microscope (Leica DMI4000B, Leica Microsystems). Hair cells were counted as present if V shapes of hair bundles were intact. The damaged/lost cells were counted in one hundred cells. Outer hair cells (OHC) were counted in the basal turns of the organs Fig. 1 . Workflow of the experiments. A total of 186 DBA/2J mice aged 1 week were divided into the mNGF-treated group (n 5 78), the vehicle group (n 5 78), and the non-treated group (n 5 30). To determine whether mNGF could ameliorate progressive hearing loss (PHL) in DBA/2J mice, saline or mNGF (saline solution, 64.8 lg/kg) was administered to DBA/2J mice of either sex by daily intramuscular injection from the 1st to the 9th week after birth. At 5, 7, and 9 weeks of age, auditory-evoked brainstem response (ABR) thresholds and distortion product oto-acoustic emission (DPOAE) were measured by a person blind to the treatments in the mNGF-treated group, the vehicle group, and the non-treated group (male 5, female 5, n 5 10 for each group). After ABR and DPOAE hearing measurements were taken, the same mice in the mNGF-treated group and the vehicle group were euthanized by intraperitoneal injection of 4% chloral hydrate to perform histological analyses (n 5 5) and cytocochleograms (n 5 5). Other mice in the mNGF-treated group and the vehicle group were also euthanized to conduct TUNEL staining (n 5 4), real time PCR (n 5 5), and western blotting (n 5 4) or Immunohistochemistry (n 5 3) analyses.
of Corti and were displayed as the percentage of missing hair cells (Han et al., 2012) .
TUNEL Staining
TUNEL staining for apoptotic nuclei was performed using a DeadEnd Colorimetric TUNEL System (Keygen Biotech) according to the manufacturer's instructions. Color development was accomplished with diaminobenzidine for 4 min. Duplicate sections were counterstained with hematoxylin, and a cover glass was mounted to each slide with Permount mounting medium. For tissue sections, TUNEL-positive cells (dark brown cells) were counted in the basal regions of the cochlear sections using a 340 objective. TUNEL-positive cells were identified by the presence of a brown-stained nucleus in the SGNs regions. The TUNEL-positive cells were calculated as the number of TUNEL-positive cells per mm 2 with the aid of Image J software. Five sections of the unilateral basal regions were evaluated in one cochlea per mouse. Four mice were used for each mNGF-treated group and vehicle group at 5, 7, and 9 weeks of age.
Assays for Gene Transcription
Mitochondria apoptosis-related genes, such as Bak, Bax, Caspase-9, and Caspase-3, were tested in this study. DBA/2J mice (n 5 5) at the ages of 5, 7, and 9 weeks were randomly chosen. Both bullae were removed from each mouse. Total RNA was extracted using Trizol (Roche Diagnostics) and cDNA was made using random primers following the FirstStrand Synthesis protocol (Takara Bio). Real-time PCR was used to determine relative gene expression levels using FastStart Universal SYBR Green Master (Roche Diagnostics) and the MyiQTM Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.). The messenger RNA (mRNA) level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the endogenous control (Table I) .
Sangon Biotech Co. Ltd. (Shanghai) synthesized all primers. Each PCR reaction contained 12.5 ll of Fast Start Universal SYBR Green Master Mix, 1 ll of cDNA, 0.75 ll of each 10 mM primer, and 7 ll of ddH 2 O. The reaction conditions were as follows: denaturing at 95 8C for 10 min, followed by 40 cycles of 95 8C for 15 s, and 60 8C for 1 min. The fold change in genes relative to GAPDH was determined by the 2 (-DDCt) method (Semaan et al., 2013) .
Western Blotting
To clarify the mechanism of the effect of mNGF, we also detected the mitochondria apoptosis related proteins, such as Bax and Caspase-3. At weeks of 5, 7, and 9, mice were euthanized with chloral hydrate (1 g/kg), and both temporal bones were immediately removed. Two cochleae were homogenized in a tube containing ice-cold lysis buffer (100 mM Tris, pH 7.4; 200 mM NaCl; 1% NP-40; 10 mM MgCl 2 ) with protease inhibitors (PMSF). Lysates were incubated for 20 min at 37 8C and then centrifuged for 30 min at 12,000 rpm at 4 8C. In addition, proteins in the supernatant were separated using 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Blots were incubated overnight with the primary antibodies against Bax (Cell Signaling Technology, Cat# 5023S Lot# RRID: AB_10557411) and Cleaved Caspase-3 (Cell Signaling Technology, Cat# 9661L Lot# RRID: AB_331441). After rinsing in TBST, the membranes were incubated with the HRP-conjugated secondary antibody (1:5000; ZSGB-Bio) for 1h. Bands were detected by chemiluminescence. Further, blots were stripped and reprobed with a GAPDH antibody (1:1000), thereby serving as a protein-loading control. According to manufacturer's data sheet, Bax (D2E11) Rabbit mAb detects endogenous levels of total Bax protein at 20 kDa (single band). The Cleaved Caspase-3 (Asp175) Antibody of activated caspase-3 detects endogenous levels of the large fragment (17/ 19 kDa, two bands) of activated caspase-3 resulting from cleavage adjacent to Asp175. This antibody does not recognize fulllength caspase-3 or other cleaved caspases. Band intensities were quantified using the Image J software (NIH). Four mice were used for each group.
Immunohistochemistry
As a supplement for detecting the mitochondria apoptosis-related proteins, such as cytochrome c and APAF1, we also used immunohistochemistry. The animals were euthanized by intraperitoneal injection of 4% chloral hydrate and fixed with 4% paraformaldehyde. The cochlear specimens were placed in a refrigerator overnight at a 4 8C and then decalcified with 10% EDTA for 7 days. The cochleae were dehydrated with 15% and 30% sucrose for 2-3 days until they sank to the bottom; then they were embedded with optimum cutting temperature (OCT) glue and sectioned into 5 lm thicknesses with cryomicrotome (Leica CM3050S). The sections were fixed by 4 8C acetone for 20 min and then washed three times with ABR thresholds in DBA/2J mice repeatedly detected at 5, 7, and 9 weeks of age (male 5, female 5, n510 for each group). Error bars: standard error of the mean. The results show that ABR thresholds at high-frequency were significantly lower in the mNGF-treated mice than those of the vehicle group and non-treated mice at the three time-points (p < 0.01).
No significant difference was found between the saline-treated groups and non-treated groups or between male and female mice. (C): The mNGF-treated mouse presented DPOAE amplitudes much higher than the saline-treated mice at 7 weeks of age. (D) DPOAE in DBA/2J mice measured at 5 and 7 weeks of age (n 5 10). DPOAE amplitudes were significantly higher in the mNGF-treated mice than in those of the salinetreated mice and non-treated mice at the two time points, Error bars: standard error of the mean. The saline-treated groups and non-treated groups had no statistically significant difference (p > 0.05). w, weeks; *indicate vehicle group and mNGF-treated group are statistically significant different (p < 0.05); ** mean vehicle group and mNGF-treated group have a statistically significant difference (p < 0.01), ABR, auditoryevoked brainstem response; DPOAE, distortion product otoacoustic emission; SPL, sound pressure level. [Color figure can be viewed at wileyonlinelibrary.com] Surface prepared basilar membranes were stained with alexa-fluor-488-phalloidin. OHC loss occurred at 9 weeks old, but no significant OHC loss could be observed at other time points; the difference between mNGF-treated and vehicle groups at 9 weeks was significant. OHC, outer hair cell; scale bars550 lm. (E) Percentage of OHC loss in cochleae at three time-points. The loss of OHC was significantly decreased at the basal turns of cochleae in the mNGF-treated group compared to that in the vehicle group at 9 weeks of age. *p < 0.05, **p < 0.01; n 5 5 at each time point; w, weeks. were used as secondary antibodies and incubated for 40 minutes at 37 8C temperature. The samples were washed three times for 5 min with 13 PBS. To label the nuclei, 4 0 , 6-diamidino-2-phenylindole (DAPI; Beyotime) was added to the samples for 5 min at room temperature before washing three times in PBS. The staining and image capture were performed as indicated above. Three mice were used for each group.
Statistical Analysis
Data are expressed as mean 6 SE, unless otherwise specified. SAS version 9.4 (SAS Institute, Inc.), proc mixed was used to perform a repeated measures analysis of variance for ABR thresholds and DPOAE data analysis. The difference between two groups for other measurements was determined by Unpaired Student t test using SPSS software (http://www-01. ibm.com/software/uk/analytics/spss/, RRID:SCR_002865); p < 0.05 was considered to be statistically significant.
RESULTS mNGF Decreases the ABR Thresholds in DBA/2J
Mice ABR thresholds measurement is well accepted for hearing functional testing both in human and mice. The high frequencies such as 32 kHz represent the function of cochlear basal turn; the lower frequencies represent the function of cochlear epical turn. Normal mice have higher hearing sensitivity at 16 kHz-24 kHz. DBA/2J mice are well-known to have early-onset progressive hearing loss (Johnson et al., 2008) . After daily treatments from 1 week of age, ABR thresholds were measured at 5, Fig. 3 . Continued 7, and 9 weeks of age to click and to tone pips of 8, 16, and 32 kHz, respectively. ABR thresholds in the mNGF group were significantly lower (10-15 dB) than those in both the vehicle group and the non-treated group for high frequencies at the three time-points (Fig. 2B ), but not significantly lower for click and 8 kHz stimuli (degrees of freedom 5 1, F 5 0.77, P > 0.05, n 5 10, a repeated-measures ANOVA with proc mixed [data not shown]). Specifically, the ABR thresholds at the frequencies (Hz) of 16 kHz and 32 Hz were significantly (10-15 dB) lower in the mNGF group than those in the vehicle group (degrees of freedom 5 1, p < 0.01, F 5 50.54, and 34.45, n 5 10 for each frequency, a repeated-measures ANOVA with proc mixed). Furthermore, in the vehicle group, the ABR thresholds at 9 weeks of age were significantly higher than those at 5 weeks of age at the frequency of 32kHz (degrees of freedom 5 2, p < 0.05, F 4.08, a repeated-measures ANOVA with proc mixed), suggesting an aging effect. There were no significant interactions between age and treatment. (Degrees of freedom 5 2, F 5 1.63, P > 0.05, n510, a repeated-measures ANOVA with proc mixed). Given that a similar aging effect has been previously reported (Johnson et al., 2008) and that there is no difference between the vehicle group and the non-treated group, for the remainder of our analysis, we only compared mNGF groups and vehicle groups that were age-matched at each of the 3 time-points with ttests. For effect sizes, Cohen's d was calculated as the difference between the means, divided by the pooled SD. The effect sizes for click and 8 kHz were between 0.09 and 0.46, except 0.67 for click at 7 weeks of age. In contrast, the effect sizes for 16 kHz and 32 kHz were between 1.06 and 2.08. There was no significant difference between male and female mice (data not shown). Therefore, for the rest of our experiments, we did not try to differentiate between genders.
mNGF Increases DPOAE Amplitudes in DBA/2J Mice DPOAE is another well-known hearing test for humans and mice, which is particularly recognized for testing the function of outer hair cells (OHCs). After testing the ABR threshold of each mouse, DPOAE was immediately measured. The level of DPOAE amplitudes in the mNGF group was generally 5-10 dB higher than that of the vehicle group at 5 and 7 weeks of ages ( Fig.  2D) (P < 0.01). Specifically, the DPOAE amplitude differences at the frequencies (Hz) of 6244, 8844, 12503, 17672, 24990, and 35344 were significantly higher in the mNGF group (degrees of freedom 5 1, p < 0. 01, F values 41.31, 20.04, 19.37, 35.78, 43.07, 9 .98 for each of them, respectively, n 5 10, a repeated-measures ANOVA with proc mixed) (Figs. 2C,D) . Furthermore, the difference in mNGF effect among those at 7 weeks of age was significantly higher than the difference in mNGF effect among those at 9 weeks of age, particularly at higher frequencies of 17672 Hz, (degrees of freedom 5 2, F 5 3.83, P < 0.05), 24990Hz, (degrees of freedom 5 2, F 5 12.78, P < 0.01), 35344Hz (degrees of freedom 5 2, F 5 9.56 P < 0.05, a repeated-measures ANOVA with proc mixed) (Fig. 2D) . These data indicate that the mNGF protected the functions of the OHCs in DBA/2J mice with the highest effect at 7 weeks of age at 24990Hz. Cohen's d at 24990Hz was the highest at 2.70, in contrast to all other significant Cohen's d values ranging between 0.94 and 1.80. The 24990Hz DPOAE represents the OHCs' function at the most sensitive frequency of hearing for mice (Muller et al., 2005) .
Histological Examination Revealed mNGF Protects Stria Vascularis, Spiral Ganglion Neurons, and Hair Cells in the Cochlea of DBA/2J Mice
We compared morphological changes in these cochlear structures caused by mNGF treatment to changes observed in the vehicle group at corresponding hearing testing ages. Lesions of the hair cells and SGNs were presented as OHC and neuronal cell loss, while stria vascularis was present as width changes. Morphological changes between the groups at the three time-points are shown in Fig. 3A . OHC loss was obvious at the age of 9 weeks, and the mNGF-treated group presented less cell loss than the vehicle group. At the other two time points, there is no significant difference between the two groups.
The survival of SGNs in the basal cochlear regions was calculated (Fig. 3C) . The protective effects of mNGF on SGNs at earlier ages (5 and 7 weeks) were significant (p < 0.05, n 5 5) and stronger than those at the later age (9 weeks).
The widths of stria vascularis in the mNGF group were thicker than those of the vehicle group (Figs. 3A,B) , but only to a significant degree at 9 weeks of age (p < 0.01, n 5 5).
OHCs were stained with Alexa Fluor 488 conjugated to phalloidin (Fig. 3D) . OHC loss was counted; the percentages of OHC loss in the cochleae at the three time-points are shown in Fig. 3E . There was barely any OHC loss at the apex and middle turns of the cochleae at the three time-points (data not shown). However, loss of OHCs was significantly less in the basal turns of cochleae in the mNGF-treated group compared to that of the vehicle group at 9 weeks of age (p < 0.01; n 5 5).
mNGF Inhibits Apoptosis of Spiral Ganglion Neuron Cells in DBA/2J Mice SGN apoptosis usually accompanies hearing loss. The mNGF-treated mice showed fewer TUNEL-positive cells (Fig. 4A) than the vehicle group at the three timepoints. Quantification and statistical analysis of the TUNEL staining showed that the number of TUNELpositive cells decreased significantly in the mNGF-treated group compared to the vehicle group (p < 0.01, n 5 4; Fig. 4B ).
mNGF Treatment Down-regulates Apoptosisrelated Genes in the Cochleae of DBA/2J Mice Apoptosis may play a potential role in the early onset of hearing loss . Gene expression profiles in the inner ears of DBA/2J mice at 5, 7, and 9 weeks of age were detected simultaneously in the mNGF-treated and vehicle groups. The results demonstrated that apoptosis-related genes, such as Bak, Bax, Caspase-9, and Caspase-3, were downregulated in the mNGF-treated group at the three time-points (Fig. 5) .
The mRNA levels of Bak and Bax, which are taken from the mitochondrial membrane, were significantly lower in the mNGF-treated group compared to the vehicle group at the 5th and 7th weeks (Figs. 5A,B ; p < 0.05) respectively, but not at the 9th week. However, the expression of Caspase-9 and Caspase 3 was significantly downregulated in the mNGF-treated group at 9 weeks of age compared to the vehicle group ( Fig. 5C ; p < 0.05). The results indicate that mNGF might downregulate apoptosis-related genes to slow hearing loss in DBA/2J mice. 
mNGF Treatment Downregulates the Expression of Apoptosis-related Proteins in Cochlea
Western blotting data in the present study indicated that mNGF treatment decreased apoptosis-related protein expression in the cochlea to protect hearing (Figs. 6A,B) . The apoptosis-related proteins Bax and Caspase-3 in the mNGF-treated group showed lower expression than the vehicle group at 7 weeks of age, and Bax at 9 weeks of age; however, there was no significant difference at 5 weeks of age. Quantification and statistical analysis of the relative intensity fold by Western blotting showed that the levels of Bax and Caspase-3 expression in the mNGFtreated group were lower than in the vehicle group (Figs.  6C,D) . Cytochrome c is released from the mitochondria and plays a critical step in the apoptotic cascade (Bouchier-Hayes et al., 2008) . The level of cytochrome c decreases in the mitochondrial fraction and increases in the cytosolic fraction when apoptosis occurs (Yan et al., 2015) . In our study, we observed that cytochrome c in the mitochondria achieved greater expression in the mNGF-treated mice than the vehicle mice at the three time-points (Fig. 6E) . Furthermore, immunostaining showed that the expressed level of APAF1 in the SGNs of basal turns was much higher in the vehicle group than in the mNGF-treated group (Fig. 6F) . In the presence of cytochrome c and dATP, APAF1 plays an essential role in apoptosis by assembling into an oligomeric apoptosome. It is also responsible for the activation of procaspase-9 and the maintenance of the enzymatic activity of processed caspase-9 (Bao et al., 2007) .
DISCUSSION mNGF Ameliorate ePHL and Related Cochlear Pathology in DBA/2J Mice
In the present study, we used DBA/2J mice to evaluate the otoprotective effects of mNGF and determined that mNGF could preserve hearing and maintain the function of OHCs in DBA/2J mice (Fig. 2) . These results were further supported by less OHC and SGNs loss and less inhibited SV degeneration in mNGF-treated cochleae compared to vehicle cochleae of DBA/2J mice (Fig. 3) . Thus, the otoprotective effects of mNGF against PHL in DBA/2J mice were demonstrated. The mNGF treatments were started at 7 days of age with the mice, but in our experience, ABR thresholds and DPOAE can only be accurately measured after 20 days of age. Therefore, we could not have performed pre-treatment testing before 7 days of age. Previous studies suggested that DBA/2J mice displayed early-onset AHL at about 3-4 weeks of age. As previously reported, the mean ABR thresholds for DBA/ 2J mice at 3 weeks for click, 8 kHz, 16 Hz, and 32 kHz were 43 6 4, 28 6 4, 28 6 18, and 53 6 12 dB SPL; while the mean thresholds for CBA/CaJ mice (a wellrecognized normal hearing strain) at 9-39 weeks were 36, 24, 15, and 39 dB SPL for the click, 8 kHz, 16 kHz, and 32 kHz stimuli, respectively (Zheng et al., 1999) . Our data showed (Fig. 2B ) that the ABR thresholds of the mNGF group at 5 and 7 weeks were quite similar to the normal values at 32 kHz in this literature. The ABR is a far-field evoked potential consisting of several peaks (I-V), representing activation of specific generators along the auditory pathway from the cochlea to the brainstem via the auditory nerve. The long-lasting effect of mNGF on ABR thresholds (Figs. 2A,B ) from 5-9 weeks of age may be a result of its effect on the pathological changes in different cochlear structures, occurring at various timepoints. For example, at 9 weeks of age, SGN may have the highest deterioration rate, whereas at this age mNGF showed a more significant effect on ABR thresholds. The treatment was terminated at 9 weeks of age because DPOAE showed that the beneficial effects of mNGF had decreased compared to the 7 weeks' data. DPOAE measuring OHC's function may reflect the highest functional Immunostaining for Cyt C in mitochondrion of SGNs in the basal turns of cochleae in DBA/2J mice aged 5, 7, and 9 weeks. Stronger signals were detected in the SGNs of the mNGF-treated group than in the vehicle group at the three time-points. (F) Immunostaining of APAF1 in SGNs of the basal turns of cochleae in DBA/ 2J mice. APAF1 was more expressed in the vehicle group than in the mNGF-treated group at the three time-points. N 5 3, Scale bar 5 50 lm. [Color figure can be viewed at wileyonlinelibrary.com] deterioration rate at around 7 weeks of age in the vehicle group, thus indicating the best window of time for the mNGF therapy. The hair cell counts in Fig. 3A seem to differ from Fig. 3D ; however, upon closer examination one can clearly see that due to a missed section or the displaced nucleus of normal hair cells, there is no hair cell loss in Fig. 3A at 5 or 7 weeks. In contrast, SGN damage is already severe at 5 weeks of age and thus mNGF treatment effectively rescued the SGNs (Figs. 3A,C) and ABR thresholds (Figs. 2A,B) at this age. The therapeutic effect of mNGF on SGN is stronger and earlier than its effect on the OHCs. The OHC damage mostly affected the basal turn of the cochlear, which is responsible for highfrequency detection. This data provides a good explanation of why mNGF had the best effect on high-frequency hearing loss (Muller et al., 2005) . These data provide morphological and functional evidence that mNGF can prevent hearing loss in an animal model. Although we expected the male mice to have more severe hearing loss, as well as a better response to the treatment (because men have significantly faster rates of threshold increase than women [Kim et al., 2010] ), our data did not find a gender difference in either hearing loss or mNGF effect.
However, therapeutic use of human NGF is limited due to the blood-brain barrier (BBB). NGF is able to cross the BBB under specific conditions, such as when the BBB has been damaged. In this paper, we observed some minor stria vascularis damage in the DBA/2J mice (Fig. 3) , which may have increased the penetration of mNGF across the blood-labyrinth barrier. In previous studies on animal models for neurotrophic treatment of hair cell loss, the treatment was mostly delivered using local drug delivery to the inner ears. But in those studies, it had a significant hearing-protective effect in noiseinduced hearing loss (Shoji et al., 2000) and drug-induced hair cell loss (Ruan et al., 1999) . Recently, in patients with a sudden sensorineural hearing loss (SSHL), a randomized/controlled clinical trial of the topical, insulinlike, growth factor-1 (IGF-1) therapy was performed and compared to intratympanic corticosteroid therapy. The positive effect of the topical IGF-1 application on hearing levels and its favorable safety profile suggest topical IGF-1 therapy as a salvage treatment for SSHL (Nakagawa et al., 2014) . To reduce systematic adverse effects, this study was performed using a topical IGF-1 application. Our study did not observe any systematic adverse effects over a 8-week period. In another study on deaf guinea pigs, the long-term effects of temporary treatment with brainderived neurotrophic factor (BDNF) showed that, after treatment cessation, the neuroprotective effect continued for at least 8 weeks (Ramekers et al., 2015) .
mNGF Preventing Hearing Loss via Suppression of Apoptosis Pathway
The molecular mechanisms underlying hearing loss are largely unknown. It is very difficult to evaluate any prophylactic efficacy of a drug and to investigate the molecular mechanisms underlying hearing loss in human patients. An alternative and complementary approach to these human studies is using mouse models (Ohmen et al., 2014) . Inbred mouse strains serve as important models for hearing loss. DBA/2J mice have homozygous mutations in Cdh23 ahl/ahl and Fscn2 ahl8/ahl8 as well as other quantitative trait loci (QTLs) that modify the severity of hearing loss (Johnson et al., 2015) . Recently, our data and the data of others show that mutations of Cdh23 gene can cause apoptosis in the inner ear (Han et al., 2012) . Apoptosis in the cochleae is widely understood to contribute to PHL (Dirks et al., 2006; Kujoth et al., 2007; Someya and Prolla, 2010; Yamasoba et al., 2013) . There are mainly two pathways that trigger apoptosis: the intrinsic pathway and the extrinsic pathway (Youle and Strasser, 2008) . The former is also known as the mitochondrial pathway (Fig. 7) , which is a Bak-dependent pathway and may be involved in the cochlear aging in DBA/2J mice (Someya et al., 2009) . By administering mNGF to DBA/ 2J mice in our study, we verified that apoptosis-related genes, especially Bak, Bax, and Caspase-3, were less expressed in mNGF-treated mice compared to control mice but varied reasonably between mRNA (Fig. 5) and/or protein (Fig. 6) levels. There are multiple posttranscriptional mechanisms involved in protein modification, such as the activation of the cleaved Caspase-3 protein. Additionally, there is no significant effect of mGNF on Bak and Bax at 9 weeks, in contrast to its effect at 5 and 7 weeks. A possible explanation is that the number of mitochondria markedly decreases at 9 weeks of age. TUNEL-positive cells in mNGF-treated mice were lower than in the vehicle group at the three timepoints tested (Fig. 4B) . These results further elucidated the apoptosis mechanisms underlying the hearing loss in DBA/2J mice.
NGF can promote neuronal survival and growth mainly by binding with TrkA receptors and p75 NTR receptors on cell surfaces. B-cell lymphoma-extra large (Bcl-xL) is one of the prosurvival members of the Bcl-2 family, which can rescue SGNs deprived of a trophic factor in vitro and in vivo (Hansen et al., 2007) . The combination of NGF and TrkA can cause Bcl-2 to be highly expressed and, thus, eventually prevent apoptosis (Sofroniew et al., 2001) . Sharing a nearly 90% homologous amino acid sequence with the NGF of humans, mNGF also plays an important regulating role in neuron survival, growth, differentiation, and maintenance (Apfel et al., 1998; Bibel and Barde, 2000; Verge et al., 1996) and it may provide a new therapeutic modality for hearing loss. In the present study, the otoprotective effects of mNGF were confirmed. We found that the otoprotective effects of mNGF were strongest at 7 weeks of age by using DPOAE (Fig. 2 C and D) . Moreover, the difference in the expression level of caspase-3 at 7 weeks of age was the most obvious compared to the other two time points with Western blotting (Fig. 6D) . Therefore, we suppose that the most effective time for mNGF treatment in DBA/2J mice is at about 7 weeks. It should be noted that we adopted the manufacturer-recommended dose for injection of mNGF, which is produced commercially in China and is the most common exogenous form of NGF, and that no abnormal activities were observed in the mice for up to 8 weeks of treatment.
In summary, our data supports our hypothesis that mNGF has a significant otoprotective effect in the PHL of DBA/2J mice and that mNGF can attenuate cochlear cell death through the Bak-dependent mitochondrial apoptosis pathways.
